Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study

• Published in: BMC cancer Vol. 22; no. 1; pp. 1 - 1043
• Main Authors: Zhang, Shaopeng, Pan, Guoqiang, Liu, Zhifeng, Kong, Yuan, Wang, Daguang
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05.10.2022; BioMed Central; BMC
• Subjects: Analysis; Blood diseases; Calibration; Cancer; Cancer surgery; Care and treatment; Chromatography; Colorectal cancer; Colorectal surgery; Diagnosis; Discriminant analysis; Energy; Ions; Liquid chromatography; Liquid chromatography–mass spectrometry; Mass spectrometry; Mass spectroscopy; Metabolites; Metabolomics; Methods; Patient outcomes; Patients; Rectal cancer; Rectum; Safe margin; Scientific imaging; Software; Surgery; Tumors; China; Germany
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10124-2

Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Keywords: Rectal cancer, Liquid chromatography-mass spectrometry, Safe margin, Metabolites